- $48.67m
- $129.31m
- $83.81m
Bluebird bio gains after cutting 25% workforce to reduce costs
Bluebird bio to cut 25% of workforce as part of restructuring (updated)
Bluebird bio to cut 25% of workforce as part of restructuring
Brief: Bluebird Bio Inc - As Result of Restructuring Will Incur Aggregate Charges Of About $3.7 Million In Cash Expenditures
Brief: Bluebird Bio Initiates Restructuring Intended To Optimize Cost Structure And Enable Quarterly Cash Flow Break-Even In The 2H25
Brief: bluebird bio And Henogen Enter Into A Master Services Agreement For Viral Vector Services
Brief: Bluebird Bio Announces Completion Of Its Restatement And Filing Of Its 2023 Form 10-K And Q1 2024 Form 10-Q
Brief: bluebird bio Announces Receipt Of Expected Notices From Nasdaq
U.S. RESEARCH ROUNDUP-Allstate, Bluebird Bio, Vicinity Motor
U.S. STOCKS ON THE MOVE-Progressive, Serve Robotics, Palo Alto Networks
U.S. STOCKS ON THE MOVE-Allstate, Progressive, Serve Robotics
Bluebird falls after tempering forecast on patients starting its gene therapies
bluebird bio Inc expected to post a loss of 64 cents a share - Earnings Preview
Bluebird bio appoints new CFO amid financial restatements (updated)
Bluebird bio appoints new CFO
Brief: Bluebird Bio Inc Appoints O. James Sterling As CFO
bluebird bio Inc expected to post a loss of 64 cents a share - Earnings Preview
Brief: Bluebird Bio Announces Completion Of First Cell Collection For Lyfgenia Gene Therapy
bluebird bio Inc expected to post a loss of 64 cents a share - Earnings Preview